“Jim’s wealth of experience in CNS drug development, coupled with his deep financial acumen, will be invaluable to our company and clinical-development strategies,” said Jeff Jonas, M.D., Chief Executive Officer of Tortugas.

Biotech Veterans Jeff Jonas and Al Robichaud to Lead Company with Investment from Cure Ventures, The Column Group, and AN Ventures